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Abstract: Molecular genetic studies of lung cancer have revealed
that clinically evident lung cancers have multiple genetic and epi-
genetic abnormalities, including DNA sequence alterations, copy
number changes, and aberrant promoter hypermethylation. To-
gether, these abnormalities result in the activation of oncogenes and
inactivation of tumor-suppressor genes. In many cases these abnor-
malities can be found in premalignant lesions and in histologically
normal lung bronchial epithelial cells. Findings suggest that lung
cancer develops through a stepwise process from normal lung
epithelial cells towards frank malignancy, which usually occurs as a
result of cigarette smoking. Lung cancer has a high morbidity
because it is difficult to detect early and is frequently resistant to
available chemotherapy and radiotherapy. New, rationally designed
early detection, chemoprevention, and therapeutic strategies based
on the growing understanding of the molecular changes important to
lung cancer are under investigation. For example, methylated tumor
DNA sequences in sputum or blood are being investigated for early
detection screening, and new treatments that specifically target
molecules such as vascular endothelial growth factor and the epi-
dermal growth factor receptor are becoming available. Meanwhile,
global gene expression signatures from individual tumors are show-
ing potential as prognostic and therapeutic indicators, such that
molecular typing of individual tumors for therapy selection is not far
away. Finally, the recent development of a model system of immor-
talized human bronchial epithelial cells, along with a paradigm shift
in the conception of cancer stem cells, promises to improve the
situation for patients with lung cancer. These advances highlight the
translation of molecular discoveries on lung cancer pathogenesis
from the laboratory to the clinic.
Key Words: Lung cancer, Molecular pathogenesis, Tyrosine kinase
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Lung cancer is the leading cause of cancer deaths in theUnited States in both sexes, with an estimated mortality of
more than 160,000 in 2006.1 Current standard therapies
include surgical resection, platinum-based doublet chemo-
therapy, and radiation therapy alone or in combination. Un-
fortunately, these therapies rarely cure the disease, and the
overall 5-year survival rate is still only 15%.1 To reduce the
incidence of lung cancer and to improve the currently poor
outcome, several important issues related to the pathogenesis
of these diseases need to be addressed by the biomedical
community. First, because 85% of lung cancers are caused by
tobacco smoke, continued efforts are required to prevent
smoking initiation and to aid in smoking cessation.2 Unfor-
tunately, one outcome of current smoking-prevention efforts
is that nearly half of all lung cancer cases are now diagnosed
in former smokers. Thus, identifying former smokers at the
highest risk of developing lung cancers remains an important
priority. Second, because most lung cancers present as ad-
vanced cases, which are not amenable to curative surgery or
radiotherapy, development of efficient early detection meth-
ods are needed. Recent advances in spiral computed tomog-
raphy scans give some hope of improved early detection, at
least for peripheral lung cancers.3,4 Also, biomarkers based
on the common molecular defects found in lung cancers, such
as methylated DNA, are being tested for clinical application.5
Third, more effective drugs that are better suited to the
molecular phenotypes of a given cancer are needed because
current standard therapy with cytotoxic drugs provides only
modest survival benefits.6
Extensive molecular genetic studies of lung cancer
show that clinically overt lung cancers have multiple genetic
and epigenetic alterations (20 per tumor).7 In addition,
several studies have demonstrated that preneoplastic cells and
histologically normal bronchial epithelium harbor many of
these abnormalities, suggesting that human lung cancer de-
velops from normal epithelial cells through a multistep pro-
cess involving successive genetic and epigenetic abnormali-
ties, usually coincident with cigarette smoking.8 These
abnormalities contribute to the initiation, development, and
maintenance of lung cancer.
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Large-scale molecular genetic studies have led to the
discovery of several potential molecular targets for therapeu-
tic design, such as vascular endothelial growth factor (VEGF)
and epidermal growth factor receptor (EGFR). Various drugs
targeted against these molecular changes have been devel-
oped and are being tested for clinical use in lung cancer
therapy (Table 1 and Figure 1). The promise of these drugs is
that they are specific for particular—often aberrant—mole-
cules that are altered in cancer cells but not in normal cells;
thus, they have a higher therapeutic ratio for cancer cells
compared with normal cells. Some of these drugs, such as the
monoclonal anti-VEGF antibody bevacizumab (Avastin),
have shown a significant impact on patient survival.9 In
addition, the recent discovery of tyrosine kinase (TK) domain
TABLE 1. Genetic Alterations Found in Lung Cancer and Drugs or Therapeutics Targeting These
Alterations
Gene Type of Alteration Drug or Therapeutics Targeting Abnormalities
EGFR Mutation and amplification Tyrosine kinase inhibitors (gefitinib, elrotinib)
Chimeric IgG monoclonal antibody (cetuximab)
HER2 Mutation and amplification Pan-ERBB tyrosine kinase inhibitor (CI-1033)
Humanized monoclonal antibody (trastuzumab)
c-KIT Overexpressed Tyrosine kinase inhibitor (imatinib)
SRC Constitutively activated Src inhibitor (dasatinib)
BRAF Mutation Raf kinase inhibitor (sorafenib)
RAS Mutation Farnesyl transferase inhibitors (tipifarnib, lonafarnib)
MEK Constitutively activated Inhibitors of MEK (CI-1040, PD325901)
PI3K/AKT/mTOR Constitutively activated PI3K inhibitor (LY294002)
mTOR inhibitor (rapamycin) and its derivatives (CCI-779, RAD001, AP23576)
BCL2 Overexpressed Antisense oligonucleotide (oblimersen sodium)
Inhibitor of BCL2 (ABT-737)
p53 Mutation and deletion p53 adenoviral vector (Advexin)
FUS1 Loss of protein expression FUS1 nanoparticles (DOTAP:Chol-FUS1)
VEGF Overexpressed Humanized monoclonal antibody (bevacizumab)
VEGFR-2 and EGFR inhibitor (ZD6474)
Telomerase Overexpressed Telomerase template antagonist (GRN163L)
EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.
FIGURE 1. Major growth transduction pathways involved in lung cancer pathogenesis and drugs targeting altered molecules
in the pathways.
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mutations in the EGFR of non-small cell lung cancers
(NSCLCs), and the finding that such tumors are particularly
sensitive to EGFR TK inhibitor (TKI) therapy, indicate the
possibility of molecular typing of tumors to aid in therapy
selection.10,11
The main aims of this review are to provide a compre-
hensive summary of the latest discoveries in the pathogenesis
of lung cancer and to discuss how some of these findings are
the subject of ongoing translational efforts to bring novel and
effective drugs to the clinic. We summarize important aspects
of lung cancer pathogenesis that include (1) the causes of
lung cancer, (2) genomic instability in lung cancer, (3)
abnormalities in growth-stimulatory signaling pathways (pro-
tooncogenes), (4) abnormalities in growth-inhibitory tumor-
suppressor pathways (tumor-suppressor genes [TSGs]), (5)
abnormalities leading to evading apoptosis, (6) cell immor-
talization and the activation of telomerase, (7) sustained
angiogenesis, and (8) abnormalities in immune response in
lung cancer and in immunotherapy for lung cancer. Finally,
we will focus on recently developed technologies and novel
concepts in lung cancer research that include (9) genome-
wide approaches for identifying regions of genetic changes,
(10) gene expression profiling by microarray technology, (11)
transgenic mouse models of lung cancer, (12) immortalized
human bronchial epithelial cell (HBEC) models, and (13) the
concept of lung cancer stem cells.
CAUSES OF LUNG CANCER
Tobacco Smoke and Lung Cancer
Tobacco smoke contains more than 60 carcinogens, and
among these, more than 20 carcinogens are strongly associ-
ated with lung cancer development.12 The most notorious of
these compounds include the polycyclic aromatic hydrocar-
bons and the tobacco-specific nitrosamine 4-(methylnitr-
sosamino)-1-(3-pyridyl)-1-butanone, both of which lead to
genetic mutations through DNA adduct formation.13 There
are two groups of enzymes that are involved in DNA adduct
formation: P450 enzymes, encoded by CYP family genes;
and glutathione S-transferases (GSTs). The carcinogenes are
metabolically activated by P450 enzymes and are either
secreted or can bind to DNA, leading to DNA adduct forma-
tion. By contrast, GSTs detoxify the intermediates of carcin-
ogens, thus protecting against adduct formation. In most
cases, these adducts are repaired, but sometimes the damage
is severe enough to cause apoptosis. Chronic exposure to
these compounds often leads to mutations in critical genes
such as p53 or RAS, which lead to the initiation or progres-
sion of the disease. Tobacco smoke also induces oxidative
DNA lesions. 8-oxoguanine is a major oxidative lesion that
causes G-to-T transversion, possibly leading to mutations in
critical genes involved in lung cancer pathogenesis. 8-ox-
oguanine is repaired by 8-oxoguanine DNA N-glycosylase 1
(OGG1) and, thus, polymorphisms in OGG1, with reduced
enzymatic activity of OGG1 are possibly associated with
increased risk for lung cancer.
Although it is generally accepted that tobacco smoke
causes lung cancer, not everyone who smokes develops lung
cancer. Epidemiologic studies have shown that smokers are
14 times more likely to develop lung cancer than nonsmok-
ers, but only about 11% of heavy smokers develop lung
cancer in their lifetime.14 As a result, some have suggested
that genetic factors may predispose people to lung cancer
development. Many studies have examined the relationship
between polymorphic variants of the genes involved in to-
bacco smoke metabolism and DNA repair pathways, includ-
ing P450 and GST family genes and OGG1, and the risk for
lung cancer, but the results of these studies have been incon-
clusive.15 Nevertheless, a case control study has shown that
low activity of OGG1 correlates with an increased risk of
lung cancer, suggesting that people with low OGG1 activity
could be good candidates for smoking-cessation programs.16
Inherited Susceptibility to Lung Cancer
Epidemiologic studies show a 2.5-fold increased risk
attributable to a family history of lung cancer after controlling
for tobacco smoke, suggesting that genetic factors other than
those related to metabolizing carcinogens from tobacco
smoke may influence a person’s susceptibility to lung can-
cer.14 A recent large-scale linkage analysis (52 pedigrees) by
the Genetic Epidemiology of Lung Cancer Consortium sug-
gests that a major autosomal susceptibility locus for inherited
lung cancer exists on 6q23-25.17 This region contains many
potential genes of interest, including SASH1, LATS1, IGF2R,
PARK2, and TCF21.17,18 If a common polymorphism is found
in one of the genes in this region that predisposes these
families to lung cancer, it could be used to screen the broader
population to identify people with the prediposing allele.
These people would be candidates for early detection and
prevention programs.
GENOMIC INSTABILITY IN LUNG CANCER
Most solid tumors are genetically unstable at two dis-
tinct levels: large-scale chromosomal instability (CIN) and
microsatellite instability (MSI).19 CIN refers to losses or
gains of whole or large portions of chromosomes. The un-
derlying mechanisms of CIN have not been fully elucidated;
mutations in mitotic checkpoint gene, such as BUB1, are
clearly associated with the CIN phenotype in colon cancer,
but they rarely occur in lung cancer.20,21 Mice heterozygous
for mad2, another mitotic checkpoint gene, develop lung
cancer at a higher rate than wild-type mice, suggesting that
CIN may be important to lung cancer pathogenesis.22
MSI is defined as a DNA sequence change of any
length attributable to insertion or deletion of the microsatel-
lite one- to four-base DNA repeating units within a tumor.23
The most widely used method for MSI study is a polymerase
chain reaction–based method, where DNA sequence changes
are detected by comparing the electrophoresis patterns of
polymerase chain reaction products targeting microsatellite
loci between tumor and normal samples from the same
individuals. Studies have reported frequencies of MSI rang-
ing from approximately 2% to approximately 70% in both
small cell lung cancers (SCLCs) and NSCLCs.24–27 The wide
variation in the studies is probably attributable to studies of
different microsatellites and different methods of analysis.
Sozzi et al.28 evaluated the usefulness of detecting microsat-
ellite alterations in plasma or serum DNA from patients with
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NSCLC as a noninvasive strategy for early detection. They
found that altered DNA sequences (either MSI or loss of
heterozygosity) could be found in 43% of blood samples from
patients with stage I disease, with no alterations found in
control cases, suggesting that detecting these altered DNA
sequences may be useful as a tool for diagnosis and early
detection screening.
ABNORMALITIES IN GROWTH-STIMULATORY
SIGNALING PATHWAYS: PROTOONCOGENES
Although there are multiple components to each of the
growth signaling pathways involved in lung cancer, we will
focus the discussion on those proteins that are frequently
affected by genetic abnormalities in cancer. It has become
clear that these mutated proteins, while driving affected cells
toward transformation, also “addict” the cells to their abnor-
mal function. This concept is referred to as “oncogene addic-
tion” and represents a cellular physiologic state in which the
continued presence of the abnormal function, although onco-
genic, also becomes required for the tumor to survive.29 This
means that if the function is removed or inhibited (e.g., by a
targeted drug), the tumor cells die. By contrast, bystander
normal cells, which are not addicted to the mutant protein, are
much less sensitive to the drug; thus, the targeted drugs have
great tumor cell specificity. The most important example of
this concept for lung cancer is EGFR TK mutation. Tumors
with mutations in EGFR are dependent on survival signals
transduced by mutant EGFR and, thus, are particularly sen-
sitive to TKIs.30 These findings have led to massive genome-
wide sequencing efforts targeting thousands of genes to find
additional mutated oncogene targets for rational therapeutics
design. Whether this approach will be similarly useful for
targeting genes frequently overexpressed but not mutated in
lung cancers, such as MYC, remains to be determined.
Receptor TKs
The EGFR Family
The EGFR family of receptors are transmembrane TK
receptors and are composed of EGFR (HER1 or ERBB1),
HER2 (EGFR2 or ERBB2/NEU), HER3 (EGFR3 or ERBB3),
and HER4 (EGFR4 or ERBB4).31 Although these four EGFR
family receptors are homologous in the TK domains (59%–
81% identity), each has unique properties: HER2 lacks a
functional ligand-binding domain, and HER3 lacks kinase
activity.31 On ligand binding, these EGFR family members
form active homo- and heterodimers, leading to autophos-
phorylation and activation of intracellular signaling cascades.
EGFR and HER2 are overexpressed in approximately 70%
and 30% of NSCLCs, respectively, but they are rarely ex-
pressed in SCLCs.7,32 There are several currently available
drugs targeting EGFR or HER2, including the small-mole-
cule TKIs gefitinib (Iressa, targeting EGFR) and erlotinib
(Tarceva, targeting EGFR), and the monoclonal antibodies
cetuximab (Erbitux, targeting EGFR) and trastuzumab (Her-
ceptin, targeting HER2).
Recently, several mutations in the TK domain of EGFR
have been described.10,11 A review of nine published studies
suggests that EGFR mutations are common (24%; 477/2000)
in NSCLC.33 These mutations are limited to the first four
exons of the TK domain and are categorized into three
different types (deletions, insertions, and missense point mu-
tations). In-frame deletions in exon 19 (44% of all mutations)
and missense mutations in exon 21 (41% of all mutations) are
the most frequent, together accounting for more than 80% of
all mutations.33 Importantly, the presence of mutations in the
TK domain correlates with tumor drug sensitivity to
TKIs.10,11 An intriguing characteristic of EGFR mutations is
that they tend to occur in a highly selected subpopulation:
adenocarcinoma histology, never-smoker, East Asian, and
female sex.34 Notably, all of these clinicopathological factors
are associated with response to TKIs.35–38
Although several studies have confirmed the close
relationship between the presence of mutant EGFR and the
response to TKIs, it is becoming evident that a subset of
NSCLC patients with mutant EGFRs do not respond to
TKIs.10,11,39 Shortly after the discovery of the EGFR muta-
tions, a second TK domain mutation (T790M) was reported
in the same tumors that have the EGFR TK domain muta-
tions.40,41 This mutation was found in four out of seven
patients who relapsed after TKI treatment, suggesting its
contribution to acquired resistance to TKIs. Nevertheless, it
should be noted that several examples of the T790M muta-
tions have occurred in lung tumors not treated with EGFR
TKIs, and often the mutation has only been in a small subset
of the tumor cells.42 This contrasts with the other EGFR TK
domain mutations that are in all tumor cells. In addition, a
germline EGFR T790M mutation has been reported to be
associated with familial NSCLC, suggesting that this muta-
tion could predispose people to lung cancer.43 There are
EGFR-targeted TKIs that inhibit EGFR with the T790M
mutation, and several derivatives are being tested clinically.44
Also, some patients without EGFR mutations respond
to TKIs. Insufficient sensitivity for detecting mutant EGFR
might be one possible explanation for this. Nevertheless,
several predictive markers other than EGFR mutation have
been reported to correlate with TKI response, including
EGFR amplification, elevated EGFR protein, HER2 amplifi-
cation, and activation of AKT protein kinase B (Vtakt murine
thymoma viral oncogene homolog 1).38,45–48 In addition, the
presence of KRAS mutation is shown to be a negative pre-
dictor for TKI response.49 These studies suggest that other
biological features besides EGFR mutation status determine
TKI response. Clinicopathological and biological factors re-
ported to be associated with TKI response are summarized in
Table 2. Among biological predictors, EGFR mutation and
amplification by fluorescence in situ hybridization are invari-
ably correlated with TKI response, whereas the results of
EGFR protein expression are conflicting.10,11,39,45,50 Also,
whether EGFR mutation predicts patient survival remains
unclear.38,51–53 Because of these conflicting data, there is still
no standard method for selecting patients with NSCLC for
TKI therapy. Nevertheless, in practice, patients whose tumors
have EGFR mutations or who are never-smokers, particularly
those with adenocarcinoma histology, female sex, and East
Asian ethnicity, often receive TKI therapy. To address this
issue, prospective clinical trials designed to incorporate the
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patient’s clinicopathological data and the molecular biologi-
cal features of the tumors, such as EGFR mutation and
amplification, are currently underway.
TKIs have been tested extensively, both alone and in
combination with cytotoxic chemotherapy. To evaluate the
efficacy of erlotinib and gefitinib as monotherapy, two well-
controlled phase III studies were conducted for these drugs.
The results of these studies show that erlotinib prolonged
survival of previously treated NSCLC patients by 2 months
(BR.21 trial), whereas gefitinib failed to show survival benefit
(Iressa Survival Evaluation in Lung Cancer trial).37,54 Be-
cause docetaxel is the only cytotoxic drug that prolonged
survival for previously treated NSCLC patients, the result of
BR.21 is encouraging.55 Despite positive preclinical studies
of the combination of TKI and chemotherapy, several phase
III studies have failed to show a survival benefit of adding
erlotinib or gefitinib to conventional chemotherapy.56,57
Clearly, we need to improve strategies that integrate TKIs
with chemotherapy and to explore combinations with other
molecularly targeted drugs.
The most common adverse effect of both TKIs (ge-
fitinib and erlotinib) and cetuximab is cutaneous rash, which
generally occurs in a dose-dependent manner and is usually
grade 1/2 rash, with no report of grade 4 (life threatening)
rash.58 Studies have suggested a correlation between the
development of rash and response/survival, suggesting the
potential use of rash as a surrogate marker for response and a
prognosis marker.58 Diarrhea is the most common nonderma-
tologic adverse event associated with TKIs, but it rarely
occurs in patients treated with cetuximab. TKI-induced diar-
rhea can be controlled by loperamid treatment in most cases,
but it is occasionally (1%) life threatening. Interstitial lung
disease (ILD) is a rare but serious adverse effect of gefitinib.
Gefitinib-induced ILD occurs more frequently in East Asian
countries (3.5%–6%) than the United States and Europe
(1.0%–1.1%), suggesting the existence of ethnicity-related
susceptibility to the development of gefitinib-induced ILD.59
Studies have reported that approximately one third of patients
who developed gefitinib-induced ILD died.60 Male sex, a
history of smoking, and coincidence of interstitial pneumonia
are reported to be predictors for development of gefitinib-
induced ILD.61
HER2 mutations occur in 2% (16/791, pooled from two
studies) of NSCLCs.62,63 All reported HER2 mutations have
been in-frame insertions in exon 20 and have targeted the
corresponding TK domain region, as in EGFR-insertion mu-
tations. Interestingly, these mutations have frequently oc-
curred in the same subpopulation as those with EGFR muta-
tions (adenocarcinoma, never-smoker, East Asian, and
female sex).34 It should be noted that this HER2 mutation
analysis was performed using an unselected sample set; thus,
it represents the penetrance of this mutation in the general
population of lung cancer patients and is not a result of
selection bias. So far, no small-molecule inhibitors have been
reported to show similar potency against HER2 mutations as
seen with EGFR TKIs. Future studies will examine whether
mutant HER2 lung cancers respond to trastuzumab.
HER4 mutations were found in five (two squamous cell
carcinomas, two adenocarcinomas, and one large-cell carci-
noma) of 217 (2.3%) NSCLC tumor samples from Asian
patients.64 By contrast with EGFR and HER2 lung cancer
mutations, four patients with HER4 mutations were male and
smokers.64
Using laser-capture microdissection Tang et al.65 have
demonstrated that EGFR mutations occur in histologically
normal bronchial epithelial cells adjacent to tumors with
EGFR mutations. This finding suggests that EGFR muta-
tional status could be useful as an early detection marker and
chemoprevention target. Two independent groups have de-
veloped transgenic mice harboring either the point or the
deletion mutation of EGFR.66,67 Both groups have demon-
strated that the mice developed lung adenocarcinomas with
very similar histology to those seen in patients with EGFR
mutations. Moreover, the persistence of the adenocarcinoma
TABLE 2. Clinicopathological and Biological Factors Reported to be Predictive for Response to
Tyrosine Kinase Inhibitors (TKIs)
Factor Association with
TKI response
Reference
Clinicopathological factor
Nonsmoking p () Shepherd et al.,37 Tsao et al.38
Female sex p () Fukuoka et al.,35 Kris et al.,36 Shepherd et al.,37 Tsao et al.38
Asian ethnicity p () Shepherd et al.,37 Tsao et al.38
Adenocarcinoma p () Shepherd et al.,37 Tsao et al.38
Biological factor
EGFR mutation p () Lynch et al.,10 Paez et al.,11 Pao et al.,39 Cappuzzo et al.45
EGFR amplification p () Tsao et al.,38 Cappuzzo et al.45
EGFR protein p () Tsao et al.,38 Cappuzzo et al.45
EGFR T790M N () Kobayashi et al.,40 Pao et al.41
HER2 amplification P () Cappuzzo et al.48
KRAS mutation N () Pao et al.49
p-AKT P () Cappuzzo et al.46
EGFR, epidermal growth factor receptor. P (), positively associated with response to TKIs; N (), negatively associated with
response to TKIs.
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absolutely requires continued mutant EGFR function. These
results suggest that mutant EGFR is required for both initia-
tion and maintenance of the tumors. Finally, lung cancers
with EGFR mutations are more sensitive to ionizing radiation
than those without EGFR mutations; this might provide a
molecular basis for combined-modality treatment involving
TKIs and radiotherapy.68
c-Kit
SCLC, but not NSCLC, frequently (40%–70%) express
both the receptor c-KIT and its ligand, stem cell factor.69
High-level coexpression of this receptor and its ligand sug-
gests that an autocrine or a paracrine loop may promote the
growth of SCLC cells. Nevertheless, unlike gastrointestinal
stromal tumors, activating c-KIT mutations in lung cancer are
very rare.70,71 Imatinib (Gleevec), an inhibitor of c-KIT ki-
nase, inhibited cell growth in some c-KIT–expressing SCLC
cell lines by inducing cell cycle arrest and/or apoptosis.72
Nevertheless, two phase II clinical studies and a mouse
xenograft study failed to show tumor regression in SCLC by
monotherapy with imatinib.73–75 Thus, if imatinib is used in
lung cancer, it would need to be combined with other agents.
RAS/RAF/MEK/ERK Pathway
The RAS family of protooncogenes (HRAS, KRAS, and
NRAS) encode 21-kDa plasma membrane–associated G-pro-
teins that regulate key signal-transduction pathways involved
in normal cellular differentiation, proliferation, and surviv-
al.76 Activating oncogenic mutations in the RAS genes are
common in several human cancers, including lung cancer.76
RAS mutations are found in 10% to 15% of NSCLCs, espe-
cially in adenocarcinoma (20%–30%), but almost never in
SCLCs.7 The mutations occur at several hot spots in the genes
affecting codons 12, 13, and 61, all of which influence
intrinsic GTPase activity.76 Although it has yet to be estab-
lished what the distinctive functions of HRAS, KRAS, and
NRAS are, approximately 90% of RAS mutations in lung
cancer are KRAS mutations. Multiple studies have shown that
oncogenic KRAS (e.g., KRASV12 mutant) activates cell-sig-
naling pathways important to cellular transformation.77 As a
result, KRAS abnormalities represent an important therapeu-
tic target. A number of drugs that target different aspects of
RAS function and metabolism have been developed and are
currently under investigation in clinical trials.76 Farnesyl
transferase inhibitors are the best-studied drugs, and two
orally bioavailable farnesyl transferase inhibitors (tipifarnib
and lonafarnib) are being tested in the combination with
cytotoxic drugs in phase III clinical trials in lung cancer.78
BRAF protein serine/threonine kinase is a downstream
effecter of the RAS pathway. Mutations of BRAF occur
frequently in melanoma (70%) but only rarely in lung cancers
(3% of NSCLCs, 12/437; pooled from three studies).79–81
Nevertheless, for those lung cancers, mutated BRAF protein
is an important and specific therapeutic target. It should be
noted that the types of BRAF mutations found in melanoma
and lung cancers are different. Thus, there may be differences
in the responses to BRAF targeted drugs between these two
types of cancers. An orally administered Raf kinase inhibitor,
sorafenib, is currently being tested in phase I and phase II
trials in a variety of cancers, including melanoma and lung
cancer.82,83
Activated BRAF phosphorylates and activates MEK1
and MEK2, which, in turn, phosphorylate and activate ERK1
and ERK2. Substrates of ERK1/2 include several proteins
involved in mitogenic signal transduction, including ELK1
and c-JUN.76 ERK1/ERK2 are constitutively activated in a
subset of lung cancer cell lines, and thus MEK and ERK are
therapeutic targets for lung cancer treatment.84 An oral MEK
inhibitor, CI-1040, and its derivative, PD03255901, are being
tested in clinical trials for lung cancer.
Phosphatidylinositol 3-Kinase/AKT/PTEN
Pathway
Phosphatidylinositol 3-kinases (PI3Ks) are lipid ki-
nases that regulate several cellular processes such as prolif-
eration, growth, apoptosis, and cytoskeletal rearrangement.85
These proteins are constitutively activated at a high frequency
in human cancers.85 PIK3CA, which encodes the 110-kDa
alpha catalytic subunit of PI3K, is mutated in several human
cancers, including 3% of NSCLCs (8/259, pooled from two
studies).86,87 Mutation in PIK3CA results in elevated lipid
kinase levels and is a therapeutic target in tumor cells with
such mutations.87 AKT is a downstream effecter of PI3Ks,
and its activation has oncogenic effects.85 Constitutive acti-
vation of AKT was reported in 16 of 17 NSCLC cell lines.88
A PI3K inhibitor, LY294002, which reduces AKT phosphor-
ylation, enhances the sensitivity of NSCLCs to chemothera-
peutic agents and radiation therapy. Thus, PI3K inhibitors
may be useful as cytotoxic and/or chemosensitizing agents
for NSCLCs.88 By contrast, the TSG phosphatase and tensin
homolog deleted on chromosome 10 (PTEN) is a negative
regulator of AKT. Whereas PTEN is infrequently mutated in
SCLC and NSCLC,89 reduced or lost PTEN protein expres-
sion is common in lung cancers.90 Loss of PTEN activity
provides another way of activating the AKT pathway in lung
cancer, and lung tumors with loss of PTEN activity are
candidates for therapy targeting this pathway.
Mammalian target of rapamycin (mTOR) is a key
downstream target of AKT kinase activity and is a central
regulator of cell growth.85 mTOR is another potential thera-
peutic target in the PI3K pathway. mTOR inhibitors, such as
the macrolide antibiotic rapamycin (sirolimus) and its deriv-
atives (CCI-779, RAD001, and AP23576), have antitumor
activity in lung cancer, and these drugs are now being
evaluated in clinical trials for lung cancer.91
Signal Transducers and Activators of
Transcription Family
The signal transducers and activators of transcription
(STAT) family consists of seven different members: STAT1,
2, 3, 4, 5A, 5B, and 6.92 The STATs are cytoplasmic proteins
that are activated by tyrosine phosphorylation, resulting in
dimer formation and translocation to the nucleus to regulate
the expression of target genes. Constitutive activation of
STAT3 and STAT5 contributes to oncogenesis in a wide
range of malignancies, including lymphoma and breast and
lung cancers, by stimulating cell proliferation and inhibiting
apoptosis through up-regulation of genes involved in these
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pathways, such as BCL-XL , Cyclin D1, and MYC.92–94 Con-
stitutive DNA-binding activity of STAT3 were shown in six
of seven NSCLC cell lines, and introduction of antisense
oligonucleotides against STAT3 or an adenoviral vector ex-
pressing a dominant-negative STAT3 resulted in apoptosis in
NSCLC cell lines with constitutively activated STAT3.94 In
addition, it has been shown that STAT3 activation is required
for cell survival and growth of NSCLC cell lines with mutant
EGFRs.93 Thus, activated STAT3 is another therapeutic tar-
get, perhaps in combination with EGFR targeted therapy.
MYC Family
The MYC gene family encodes three nuclear phospho-
proteins (MYC, MYCN, and MYCL), which heterodimerize
with MAX proteins and function as transcription factors for
genes in a variety of cellular processes, including cell growth,
cell proliferation, and apoptosis.95 Amplification of one mem-
ber of the MYC family occurs in 18% to 31% of SCLCs and
in 8% to 20% of NSCLCs.96 MYC amplification occurs in
both SCLC and NSCLC, whereas MYCN and MYCL ampli-
fications nearly always occur in SCLC.
ABNORMALITIES IN GROWTH-INHIBITORY
TUMOR-SUPPRESSOR PATHWAYS: TSGS
The p53 Pathway
The TSG p53, located on chromosome 17p13.1, en-
codes a protein that functions as a transcription factor. p53
protein is stabilized in response to multiple stimuli including
oncogenes, hypoxia, and DNA damage. p53 activity leads to
the expression of downstream genes involved in a cell cycle
arrest to permit repair or initiate apoptosis.97 p53 is the most
frequently mutated gene in human cancers; p53 is inactivated
by mutation in approximately 90% of SCLCs and in approx-
imately 50% of NSCLCs, respectively.98,99 Most inactivating
mutations are point mutations in the DNA binding domain
(missense mutation, 70%–80%), but homozygous deletions
also occur. Some point mutations (missense) in p53 confer a
gain-of-function phenotype that contributes to increased ag-
gressiveness in several types of cancer, including lung can-
cer.100,101 p53 mutations in lung cancer correlate with ciga-
rette smoking and, more specifically, G–T transversions,
which are the classic type of mutation caused by tobacco
smoke carcinogens.98
When wild-type p53 is reexpressed in lung cancer cells
with mutant or deleted p53, the tumor cells undergo apopto-
sis.102 These findings have led to clinical trials investigating
p53 gene–replacement therapy. In fact, clinical trials of p53
gene replacement using a retrovirus p53-expression vector in
patients with NSCLCs have shown evidence of antitumor
activity and the feasibility and safety of gene therapy.103
INGN 201 (Ad5CMV-p53, Advexin), a replication-impaired
p53 adenoviral vector, has been evaluated in clinical trials; it
is both safe and effective for the treatment of several different
types of cancer, including lung cancer.104 Nevertheless, a
clear clinical benefit of these p53 gene therapies in random-
ized controlled studies has yet to be demonstrated. As with
any type of gene therapy (virus based), one needs to consider
the potential risk of treating patients with live virus, because
many aspects of biology of the wild-type adenovirus remain
to be explored.105
There are two important upstream regulators in the p53
pathway: MDM2 and p14ARF. MDM2 is an E3 ubiquitin
ligase that functions as an oncogene by reducing p53 levels
through enhancing proteasome-dependent degradation. Am-
plifications of MDM2 have been reported in approximately
6% of NSCLCs, resulting in loss of p53 function.106 The TSG
p14ARF is an alternative reading frame variant of the p16INK4a
locus (9p21) and encodes a protein that enhances p53 activity
by binding to MDM2, leading to the stabilization of p53.
Immunohistochemical analyses of p14ARF on lung cancers
have shown that p14ARF protein expression is lost in approx-
imately 65% of SCLCs and approximately 40% of
NSCLCs.107,108 Thus, loss of p14ARF may contribute to loss
of p53 expression and function.
The p16INK4a–Cyclind1-CDK4-RB Pathway
The p16INK4a–CyclinD1-CDK4-RB pathway regulates
the cell cycle at the G1/S transition. The RB gene was initially
identified as a TSG in retinoblastoma and was the first TSG
to be cloned.109 Subsequently, it was found that alteration of
one of the four components in this pathway occurs in nearly
all human cancers.110 Hypophosphorylated RB exerts its
tumor-suppressor activity by binding to E2F transcription
factor, which is essential for G1/S transition. Once RB is
hyperphosphorylated by the CyclinD1/CDK4 complex, it
releases E2F, resulting in transition from G1 to S. Thus,
absent or mutated RB leads to loss of the G1/S checkpoint.
Absent or mutant RB protein is found in approximately 90%
of SCLCs and in approximately 15% to 30% of
NSCLCs.111,112
Another regulator of RB function, p16INK4a, keeps RB
in the unphosphorylated state (and growth-suppressing mode)
by preventing CDK4 from phosphorylating RB. Thus, loss of
p16INK4a function results in loss of function of the RB
pathway. In contrast to RB, p16INK4a is very frequently
inactivated in NSCLCs (70%) but is rarely altered in SCLCs.
Inactivation of p16INK4a is caused by homozygous deletion,
coding region mutations, and promoter hypermethylation.
Finally, overexpression of either CDK4 or Cyclin D1 inhibits
RB pathway function by blocking the growth-suppressing
activity of p16INK4a.110 CDK4 is amplified in a subset of
NSCLCs.113,114 Cyclin D1 is overexpressed in more than 40%
of NSCLCs, as assessed by immunohistochemistry.115 Over-
expression of Cyclin D1 in normal-appearing bronchial epi-
thelium of patients with NSCLCs has been found to be
associated with smoking and correlates with shorter survival,
suggesting the possible utility of Cyclin D1 as a molecular
marker to identify high-risk individuals.116
Transforming Growth Factor Beta Signaling
Transforming growth factor beta (TGF-) is a multi-
functional cytokine that regulates several cellular process,
including proliferation, cell survival, and immunosurveil-
lance.117 The mechanism for TGF- signaling has been elu-
cidated. TGF- ligands bind to type II TGF- receptor
(TRII) directly or through type III TGF- receptor
(TRIII), leading TRII to form heterodimers with type I
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TGF- receptors (TRI). Then, TRII activates TRI by
phosphorylation. Activated TRI phosphorylates two down-
stream cytoplasmic transducers, SMAD2 and SMAD3. Phos-
phorylated SMAD2 or SMAD3 associates with SMAD4, and
they translocate into the nucleus, leading to the activation of
target genes.
TGF- plays a paradoxical role in lung cancer. TGF-
inhibits cell proliferation in both SCLC and NSCLC cells and
induces apoptosis. Nevertheless, at the later stage of lung
cancer tumorigenesis, TGF- induces angiogenesis, and at
this stage, the growth-inhibitory effect of TGF- is lost by
several different mechanisms. In SCLCs, this can be ac-
counted for by the frequent decrease of TRII in SCLC
cells.118 In NSCLCs, decreased expression of TRII is not
frequent, but mutations in SMAD2 and SMAD4 occur, lead-
ing to inhibition of TGF- signaling.119,120
3p TSGs
3p Loss as an Early Event in Lung Cancer
Pathogenesis
Allele loss involving chromosome arm 3p is one of the
most frequent (100% in SCLC and 90% in NSCLC) and
earliest genetic alterations found in lung cancer and may
affect more than one TSG. Three discrete regions of 3p loss
have been identified by allelotyping in lung cancers, includ-
ing a 600-kb segment at the 3p21.3, 3p14.2 (FHIT/FRAB3),
and 3p12 (ROBO1/DUTT1) regions. Wistuba et al.8 per-
formed high-resolution chromosome allelotyping using a
panel of 28 3p markers and showed that 3p losses were found
in 96% of lung cancers and 78% of preneoplastic/preinvasive
lesions, with the size and the frequency of 3p allele loss
progressively increasing as severity of histopathological pre-
neoplastic/preinvasive changes increased. Thus, these 3p ge-
netic changes occur early in lung cancer pathogenesis. There
are several genes in the 3p21.3 region closely associated with
one another that have tumor-suppressor activity.121 These
rarely mutate, but they often lose their expression by epige-
netic mechanisms. The four that have been best studied are
RASSF1A, FUS1, SEMA3B, and SEMA3F while two others
are NPRL2 and 101F6.
RASSF1A
RASSF1A rarely mutates in lung cancer, but its expres-
sion is lost by tumor-acquired promoter methylation in ap-
proximately 90% of SCLCs and approximately 50% of
NSCLCs.122,123 RASSF1A has the ability to suppress the
growth of lung cancer cell lines in tissue culture and in
immunodeprived mice.122,123 Functional analysis of
RASSF1A has shown that it is involved in multiple pathways
critical to cancer pathogenesis, including cell cycle, apopto-
sis, and microtubule stability.124
FUS1
FUS1 is located directly adjacent to RASSF1A 125
FUS1 also rarely mutates in lung cancers, and its mRNA is
usually expressed.126 Nevertheless, FUS1 protein expression
is frequently lost in lung cancer for unknown mechanisms but
detected in normal lung tissues. Wild-type FUS1, but not
tumor-acquired mutant FUS1, induces G1 growth arrest and
apoptosis.126,127 Administration of the FUS1 gene with a
nonviral vector, DOTAP: cholesterol, inhibits cancer cell
growth in vitro and in vivo, providing the rationale for using
FUS1 gene therapy for local control and for systemic treat-
ment of lung tumors in clinical trials now underway.128
SEMA3B and SEMA3F
SEMA3B and SEMA3F are also located at 3p21.3 (very
near RASSF1A and FUS1). They are secreted, soluble mem-
bers of the semaphorin family, important in axonal guid-
ance.129,130 Wild-type SEMA3B, but not tumor-acquired sin-
gle–amino acid missense mutants of SEMA3B, induces
apoptosis when reexpressed in lung cancers or added as
soluble molecules.131,132 One mechanism of such tumor inhi-
bition is through its ability to block VEGF autocrine activi-
ty.131 The growth-inhibitory effects of SEMA3F are also
observed in rat xenografts of NSCLC.133 Because both
SEMA3B and SEMA3F are soluble, secreted proteins, they
are promising candidates as drugs for systemic treatment.
Other 3p genes that are located at regions other than
3p21.3 and that have good evidence for tumor-suppressor
activity include FHIT and RAR.
FHIT
FHIT is located in 3p14.2, one of the most common
fragile sites of the human genome. FHIT is homozygously
deleted in lung cancer, and its aberrant transcripts are fre-
quently found in lung cancers.134 Also, expression of FHIT
protein is lost in approximately 50% of lung cancers.135
Several studies have shown the ability of reexpressed FHIT to
induce apoptosis in lung cancer.136
RAR
The RAR gene is located in the 3p24 region and
functions as a receptor for retinoic acid. Although RAR is
not mutated in lung cancer, it is methylated in 72% of SCLCs
and in 41% of NSCLCs, leading to loss of its expression.137
Reintroduction of RAR2 into epidermoid lung cancer cell
lines suppresses their growth in the culture and in nude
mice.138 For RAR-expressing lung cancers, retinoic acid
ligands have long been considered for therapy, but no results
of consistent therapeutic efficacy have been reported for overt
lung cancers.
In summary, 3p allele losses occur almost universally
in lung cancer and also in preneoplastic/preinvasive lesions
involving at least three very small, defined regions (3p21,
3p12, and 3p14.2), and some of the genes located in these
regions have tumor-suppressor activity. These observations
have led to the conclusion that 3p allele loss contributes to
lung cancer initiation and development through inactivating
multiple TSGs. Because of the early changes in the 3p
chromosome regions (occurring in histologically normal lung
epithelium), the presence of 3p allele loss and inactivation of
expression of these 3p TSGs may be of use in determining
smoking-related field effects. The successful results of sys-
temic administration of FUS1 in immunocompromised mice
have led to the development of a clinical trial and treatment
of patients with systemically administered (via lipid-based
nanoparticles) FUS1 gene therapy.
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Epigenetic Changes in Lung Cancer: DNA
Promoter Methylation Changes as a
Mechanism for Inactivating TSGs
CpG dinucleotides are clustered in the promoter regions
of approximately 50% of all protein coding genes in the DNA
elements that are called CpG islands. Hypermethylation of
cytosine in CpG islands in the promoter regions of TSGs
leads to loss of expression of the associated genes, contrib-
uting to the initiation and progression of human cancer.139
Promoter hypermethylation has been observed in nearly all
human cancers.139 More than 80 genes have been reported to
be hypermethylated in lung cancer, including RARB, TIMP3,
p16INK4a, RASSF1A, MGMT, FHIT, DAPK, ECAD, and
GSTP1.140 Several studies have analyzed the methylation
status of multiple genes in lung cancer and have shown that
most lung cancers have multiple aberrantly methylated
genes.141
Detecting methylated DNA sequences in biological
fluids (sputum, blood) is potentially a powerful tool for early
detection of lung cancer. Some recent studies have shown
that hypermathylation of p16INK4a is detectable in sputum or
exfoliated lung cells before lung cancer diagnosis.142 Belin-
sky et al.5 conducted a seminested case-controlled study to
evaluate the ability of examining a panel of genes in sputum
to identify people at high risk of lung cancer. They have
demonstrated that detection of methylation of three or more
genes out of the six selected genes correlated with a 6.5-fold
increased risk of developing lung cancer, with a sensitivity
and specificity of 64%. This result clearly warrants further
prospective studies, perhaps including a larger set of genes.
Recently, by using a genome-wide approach, we have iden-
tified 132 genes, many of which were shown to be methylated
in lung cancers compared with normal lungs with high
specificity, thus providing a large new panel of genes to use
for early detection.143 Interestingly, most of these genes have
not been previously studied in lung cancer.
In contrast to gene mutation, promoter hypermethyl-
ation is a reversible process, making it a very attractive target
for cancer therapy. In fact, an inhibitor of DNA methylation,
azacitidine (Vidaza), prolongs survival in patients with my-
elodysplastic syndrome144, but its efficacy for lung cancer
treatment is unknown. Histone deacetylation is another epi-
genetic change that inhibits gene expression. Drugs that
reverse gene silencing by inhibiting histone deacetylation,
such as suberoylanilide hydroxamic acid and depsipeptide,
are either in or are being considered for lung cancer clinical
trials.
ABNORMALITIES LEADING TO EVASION
OF APOPTOSIS
In addition to uncontrolled growth, evading apoptosis is
another important property of cancer cells.152 The BCL2
protein inhibits apoptosis and is overexpressed in both SCLC
(75%–95%) and NSCLC (10%–35%).7 Antisense oligonucle-
otides targeted to BCL2, oblimersen sodium (Genasense),
enhance the efficacy of standard chemotherapy in several
animal models of cancer.145 Randomized Phase II trials of
oblimersen in combination with cytotoxic chemotherapy for
SCLC and NSCLC are currently being conducted.146 Re-
cently, ABT-737, a potent inhibitor of BCL-2, BCL-XL, and
BCL-w, has shown efficacy in xenograft models of SCLC
and enhances the activity of paclitaxel against A549 NSCLC
cells, providing a rationale for its use in clinical trials for lung
cancer as monotherapy or in combination with cytotoxic
drugs.147 BAX is a BCL-2–related protein that promotes
apoptosis and is a downstream transcription target of p53.148
An inverse relationship between BAX and BCL-2 expression
is seen in SCLC but not in carcinoids, suggesting that the
aggressiveness of neuroendocrine lung tumors may be corre-
lated with apoptosis-related factors.149
CELL IMMORTALIZATION AND THE
ACTIVATION OF TELOMERASE
Telomeres are repetitive sequences, composed of
TTAGGG and localized at the end of mammalian chromo-
some, that protect chromosomes from degradation and loss of
essential genes.150 Telomeres shorten after each round of cell
division, limiting the life span of the cells.151 The enzyme
telomerase maintains telomeric repeats by elongating telo-
meric DNA by reverse transcription, and its activity is largely
determined by the expression levels of hTERT, which is the
protein catalytic subunit of telomerase.150 Up-regulation of
telomerase is almost universal in human cancers and is
thought to contribute to the early immortalization steps of
tumorigenesis, which is one of the hallmarks of human
malignancies.152 Approximately 80% of NSCLCs and nearly
100% of SCLCs have detectable levels of telomerase.153 High
telomerase activity in primary NSCLCs is detected frequently
in tumors with high tumor cell–proliferation rates and ad-
vanced pathological stage, implying that expression of telom-
erase may also contribute to the later stages of lung cancer
progression.153 The novel telomerase template antagonist
GRN163L, which targets RNA template region of hTR,
inhibits anchorage-independent growth and in vivo xenograft
tumor growth of lung cancer cells,154 providing the rationale
for its use in clinical trials of lung cancer treatment. This drug
may be effective against lung cancer stem cells (discussed
later).
SUSTAINED ANGIOGENESIS
One of the hallmarks of cancer is the ability to stimulate
angiogenesis; tumor growth beyond the size of 2 mm3 re-
quires this activity.152,155 Several studies have demonstrated
that elevated angiogenesis in lung cancer measured by mi-
crovessel density significantly correlates with the incidence
of metastasis and poor survival.156
VEGF
VEGF plays the most critical role in angiogenesis, and
lung cancers frequently produce high levels of VEGF.157
Bevacizumab, a monoclonal antibody that neutralizes all
VEGF isoforms, has been tested clinically. Recently, the
addition of bevacizumab to chemotherapy regimens with
paclitaxel and carboplatin in patients with advanced nonsqua-
mous NSCLC provided a significant survival advantage.9 The
results of this study were dramatic and provided a major
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impetus to continue work on VEGF antagonists in lung
cancer. An occasional but serious life-threatening side effect
(pulmonary hemorrhage) of bevacizumab treatment has been
observed, showing the importance of patient selection and
monitoring for this therapy.9 ZD6474 is a dual kinase inhib-
itor that targets both VEGF receptor and EGFR. The combi-
nation of ZD6474 and docetaxel as a second-line therapy in
a phase II clinical trial improved progression-free survival in
patients with advanced disease.158 The results from this trial
provide further confirmation of the importance of this target
for lung cancer.
ABNORMALITIES IN IMMUNE RESPONSE IN
LUNG CANCER AND IMMUNOTHERAPY FOR
LUNG CANCER
Molecular Abnormalities in Immune Response
Found in Lung Cancer
Evidence suggests that immune responses against solid
tumors exist. For example, spontaneous tumor regression
suggests that tumors were rejected by immunologic host
response. Nevertheless, cancers usually escape host immune
responses, using several different mechanisms. For example,
the major histocompatibility complex class I molecule, which
mediates presentation of endogenous antigen peptides to
cytotoxic T-lymphocytes, can be down-regulated in lung
cancer.159 Another mechanism used by lung tumors to escape
immune surveillance is the expression of Fas ligand.160 Sol-
uble Fas ligand causes activated T cells, but not lung cancer
cells, to undergo apoptosis.
Immunotherapy for Lung Cancer
Therapeutic interventions that kill cancer cells by in-
ducing immune responses against cancer cells are attractive
because of the potential of the immune response to be both
tumor specific and tumor systemic in nature. Two active areas
of immunotherapy include active vaccination and adoptive
T-cell transfer (ACT) therapies.
Active vaccination therapy for lung cancer has been
a challenge because of the poor antigenic characterization
of lung tumors and their ability to escape the immune
response. Recently, Nemunaitis et al.161 have shown en-
couraging clinical results in patients with NSCLC immu-
nized with autologous tumor cell vaccines expressing
granulocyte macrophage colony–stimulating factor. Gran-
ulocyte macrophage colony–stimulating factor was intro-
duced to enhance tumor antigen recognition. Nemunaitis et
al.161 conducted a phase I/II multicenter trial in patients
with NSCLC and demonstrated proof of principle for this
treatment modality, with three durable complete response
cases out of 33 advanced stage patients. These results
warrant further investigation.
ACT involves obtaining tumor-reactive T cells (tumor-
infiltrating cells or circulating blood lymphocytes), expand-
ing the cells in vitro, and then reinfusing them into the
patient.162 ACT has been shown to have clinical benefits in
patients with malignant melanoma.163 Nevertheless, because
of several difficulties in obtaining enough tumor-reactive T
cells from patients with lung cancer, the effectiveness of ACT
for lung cancer has yet to be demonstrated.
NEW TECHNOLOGIES AND NOVEL CONCEPTS
IN LUNG CANCER RESEARCH
Genome-wide Approaches for Identifying
Regions of Genetic Changes
A variety of genome-wide approaches with increas-
ingly higher resolution have been used to identify genomic
areas of amplification, deletion, and loss of heterozygosity in
human lung cancer. These include karyotypic studies, chro-
mosome-based comparative genomic hybridization (CGH),
array CGH (array-based version of CGH), genome-wide
microsatellite analysis, and single-nucleotide polymorphism
array analysis.114,164–168 The goal of these studies is to sys-
temically identify genes that have been genetically altered
during lung cancer pathogenesis, including classic oncogenes
and TSGs, and those involved in other oncogenic capabilities
of lung cancer described above.
Karyotypic analysis provided the first information on
genetic changes in lung cancer (Table 3).167 Subsequent
studies using chromosome-based CGH have better defined
chromosomal gains and losses and have revealed nonrandom
gains and losses of particular portions of chromosomes that
were not identified by conventional karyotypic analysis (Ta-
ble 3).164 Modern genetic analysis techniques such as array
CGH and single-nucleotide polymorphism array have helped
identify even smaller regions of copy number alter-
ations.114,165,168 Besides the well-known regions, such as
amplifications of MYC family genes, several novel recur-
rently altered loci, including homozygous deletions of 9p23
and 3q25 in SCLC and NSCLC, and amplifications of
8q12-13 in SCLC, 8p12, 12p11, 20q11, and 22q11in NSCLC,
have been found.114,168 Many groups have focused on iden-
tifying specific genes with abnormalities in these regions
(Table 3). Yet, despite these efforts, a number of well-defined
loci still require the genes involved in malignancy to be
identified. These are summarized in Table 3.
Gene Expression Profiling by Microarray
Technology
Oligonucleotide and cDNA microarrays are now
widely available and are powerful tools for analyzing global
gene expression changes in lung cancers compared with
normal tissues. Possible applications of this technology in
cancer research include (1) to classify subtypes of cancer, (2)
to predict prognosis, (3) to predict the response of cancers to
therapeutic interventions, (4) to find markers for early detec-
tion of cancer, and (5) to find new TSGs or oncogenes
involved in cancer pathogenesis.
As reviewed by Meyerson et al.,169 three studies have
demonstrated that gene expression patterns using microarray
technology are able to recapitulate the conventional morpho-
logic classification of lung tumors into squamous, large cell,
small cell, and adenocarcinoma. Many of the differentially
regulated genes in different lung cancer histologic types
overlapped between the studies. In addition, two of these
studies found that adenocarcinomas could be placed in sub-
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groups that correlated with patient survival.169 Furthermore,
using different microarray platforms, three independent co-
horts of patients with adenocarcinoma were classified into
three subtypes correlated to clinically relevant outcomes,
demonstrating the reproducible ability of DNA microarray to
identify clinically relevant subtypes of adenocarcinomas.170
Adjuvant chemotherapy for NSCLCs is becoming a
standard therapy because of its survival benefit. Thus, there is
a strong need to identify patients at high risk of recurrence
who will benefit from adjuvant chemotherapy. The current
clinical stage-based classification method is not precise, and
there is need for a method to identify patients in such a
subgroup. To predict the prognosis of early-stage NSCLC
patients accurately, Potti et al.171 developed a new model,
termed “metagene,” which integrates various forms of data,
including clinical variables and multiple gene-expression
profiles. They have shown that the model predicted recur-
rence significantly better than a model that included only
clinical data. This promising result warrants testing of this
model in prospective phase III clinical trials.
Several studies have identified the sets of genes in lung
cancer whose expression levels are associated with responses
of tumors to antitumor drugs.172 Furthermore, gene expres-
sion signatures involved in oncogenic pathways such as RAS
and MYC pathways were described and were found to be
significantly correlated with the prognosis of patients and
sensitivity to cytotoxic drugs in three types of cancers, in-
cluding NSCLC.173 This provides a basis for using gene
expression signatures of oncogenic pathways that are dereg-
ulated in clinical tumors as a guide to select therapeutics for
patients with these tumors.
Spira et al.174 compared the gene expression profiles of
human airway epithelial cells obtained by bronchoscopy from
current, former, and never-smokers and identified approxi-
mately 100 genes differentially expressed between current
smokers and never-smokers. They also found that changes in
expression levels of several smoking-induced genes, includ-
ing potential TSGs and oncogenes, persisted after cessation
of smoking, which could be a possible explanation for the
fact that approximately 50% of all new lung cancer cases
occur in former smokers. The SIEGE (Smoking Induced
Epithelial Gene Expression) database, which has Affymetrix
array data on bronchial epitheliums from current, former, and
never-smokers, in addition to their relevant clinical data, was
created to facilitate the identification of an airway gene
expression signature to predict the risk of lung cancer devel-
opment among smokers.175
These studies have shown that microarray technology is
a robust tool for classifying tumors and may be useful for
predicting the prognosis of patients and their sensitivity to
therapies.
Transgenic Mouse Models of Lung Cancer
Mouse models that recapitulate the carcinogenic pro-
cess of human lung cancer have substantial advantages over
in vitro tissue culture systems. For example, mouse models
have a complete physiological environment and allow anal-
ysis of host–tumor interactions and angiogenesis, which can-
not be studied in tissue culture. There are also several limi-TA
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tations of mouse models. Most importantly, there are
significant differences in the process of tumor development
between humans and mice. Whereas introduction of one to
three genetic changes is sufficient to transform murine cells
from several different types of tissues, additional genetic
changes (more than three) are required to transform corre-
sponding human cells; thus, there is a significant difference in
the susceptibility to transformation between murine and hu-
man cells. We need to understand the advantages and disad-
vantages of mouse and human models to let them comple-
ment each other to facilitate the study of carcinogenic process
of lung cancer.
Several different types of transgenic mouse models of
lung cancer have been developed with recent innovative
strategies. In particular, bitransgenic models using Cre/LoxP
recombination or tetracycline-inducible gene expression sys-
tems have enabled regulation of gene expression in mice in a
timely, spatially controlled manner. Two groups have engi-
neered mouse strains harboring conditional mutant Kras al-
leles that are expressed only after Cre/LoxP-mediated recom-
bination occurs. Both groups have shown that somatic
activation of oncogenic Kras induces lung adenocarcinoma,
demonstrating the contributions of oncogenic Kras to lung
cancer pathogenesis.176 Also, using a Cre/LoxP-mediated
recombination system, Olive et al.177 have shown that so-
matic activation of point mutations of p53 caused lung
adenocarcinoma in mice, whereas loss of p53 did not cause
any cancer, demonstrating the gain-of-function nature of
mutant p53 in vivo. Moreover, Meuwissen et al.178 developed
a mouse model of SCLC by inactivating both Rb and p53,
using a Cre/LoxP recombination system.
Immortalized HBEC Models
To systemically test the importance of the multiple
different gene alterations (including expression changes)
found in lung cancer, we developed a series of HBECs,
immortalized with cdk4 (providing a bypass of p16INK4a) and
hTERT (providing for maintenance of the ends of chromo-
somes). Both p16INK4a loss of function and telomerase ex-
pression are almost universally altered in human lung can-
cers.179 These HBECs are immortal, can be cloned, and can
be genetically manipulated, but they do not form soft agar
colonies or tumors in nude mice, and they are able to
differentiate into a pseudostratified epithelium structure, with
a histology very similar to that of normal human bronchial
epithelium in organotypic three-dimensional culture.180,181 A
great advantage of this system is that the immortalization is
performed without the use of viral oncoproteins.
This is an attractive model system for analyzing the
multistep pathogenesis of lung cancer. For example, HBECs
manipulated to have mutant KRASV12, p53 knockdown, or
mutant EGFR, alone or in various combinations, acquired the
ability to grow in soft agar and invade in three-dimensional
organotypic cultures.180 Nevertheless, the combination of
four alterations (p16 bypass, telomerase, p53 abrogation, and
mutant KRAS or mutant EGFR) was not sufficient to induce
tumor formation in nude mice.180 Thus, more than four such
oncogenic changes are needed. These results indicate that the
HBEC system is a powerful new approach to assess the
contribution of individual and combinatorial genetic alter-
ations to lung cancer pathogenesis. Another possible use of
the HBEC system is to evaluate the ability of tobacco smoke
and other carcinogens to transform normal epithelial cells to
malignant or premalignant cells.
The Concept of Lung Cancer Stem Cells
The cancer stem cell hypothesis posits that a cancer
stem cell has the ability of self-renewal: dividing to give rise
to another malignant stem cell and a cancer “progenitor” cell
that give rise to the phenotypically diverse tumor cell popu-
lation.182 In fact, a gene expression study found that lung
cancers that expressed a “stem cell gene program” had worse
survival than those that did not.183 The concept of cancer
stem cells is very important for cancer treatment. It is hy-
pothesized that cancer stem cells can escape from the cyto-
toxic effects of chemotherapy and radiotherapy because of
their low proliferation rate and potential drug resistance
related to drug transporter expression. If this is true, then
therapeutic interventions that target cancer stem cells are
needed.
Evidence for cancer stem cells was first demonstrated
in hematologic malignancies.184 Subsequently, cancer stem-
like tumor-initiating cells have been identified in breast and
central nervous system tumors.185,186 Although direct evi-
dence for the existence of cancer stem cells in lung cancer has
yet to be shown, in the Kras mouse model of lung cancer,
Kim et al.187 isolated a stem cell population at the region of
the bronchioalveolar duct junction that had the ability to
undergo self-renewal and differentiation; these are referred as
to bronchioalveolar stem cells. Furthermore, Kim et al.187
have shown that introduction of oncogenic Kras caused these
putative stem cells to expand, suggesting that these cells are
the precursors of adenocarcinoma of the lung. Clearly, more
work is needed to prove the existence of lung cancer stem
cells, and methodologies for isolating and characterizing lung
cancer stem cells are under development.
Conclusions and Future Perspectives
Molecular analysis of lung cancer has provided a great
deal of information on the molecular abnormalities in lung
cancer. On the basis of this information, new methods of
early detection, prevention, and therapeutic design for lung
cancer have been developed, and some of these methods have
shown promising results. Nevertheless, future effort needs to
be focused on important points. First, it is an important
priority to develop methods of detecting lung cancer at early
stage. Combinations of spiral computed tomography screen-
ing, genetic epidemiology, serum proteomics, and biomarkers
for lung cancer, such as methylated DNA in sputum, could
serve such methods. Second, to find better molecular targets
for therapeutic design, global searches for targets that have
the most impact on malignant behaviors of lung cancer are
necessary. The HBEC system will serve as a powerful tool
for such studies. Third, because lung cancers are heteroge-
neous diseases, both at the molecular level and in terms of
clinical behavior, the development of more individualized
treatment is necessary. The recent discovery of the correla-
tion between EGFR mutations and responses to TKI therapy
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shows the possibility of molecular typing of tumors to aid in
therapy selection for individual lung cancer patients. Never-
theless, it remains unclear whether EGFR mutation and other
biological features can predict survival of patients treated
with TKIs; prospective clinical trials are being conducted to
validate these biological predictors. A long-term goal is that
treatments for individual patients could be decided on the
basis of molecular profiling of the tumors, using global
strategies such as microarray and proteomics analyses on
tumor species or in blood from patients. Fourth, it is neces-
sary to develop methods for the efficient exploration of better
combinations of targeted drugs. Because lung cancers have
multiple changes, it would be reasonable to combine several
targeted drugs. Finally, identification of the molecular targets
that are important for a cancer stem cell population will be
crucial for developing curative systemic therapy.
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